Riskpilot← Back to searchSign inGet full accessPULMOPHARMA ApS
APSActiveCVR 36428023Bøgebjerg 2, 2. 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 2014— employees
Revenue 2024
DKK -20K
-57% vs 2023
EBITDA margin
100.0%
+57% vs 2023
Equity ratio
79.1%
Financial strength
Net profit 2024
DKK -20K
+57% vs 2023
| Revenue | DKK -20K | -57% |
| EBITDA | DKK -20K | +57% |
| Net profit | DKK -20K | +57% |
| Total assets | DKK 9,3M | +5% |
| Equity | DKK 7,4M | +0% |
| Employees | — | — |
Legal name
PULMOPHARMA ApS
CVR number
36428023
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. november 2014
Share capital
DKK 47.945
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikling af et nyt medicinsk præparat.
Address
Bøgebjerg 2, 2. 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -6 | 0 | -120 | -292 | -9 | -1 | -80 | -56 | -47 | -20 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -6 | 0 | -120 | -292 | -9 | -1 | -80 | -56 | -47 | -20 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -6 | 0 | -120 | -292 | -9 | -1 | -80 | -56 | -47 | -20 |
| Net financials | 0 | 0 | -3 | -10 | -17 | -18 | -13 | -6 | 0 | 0 |
| Profit before tax | -6 | 0 | -123 | -302 | -26 | -19 | -93 | -63 | -47 | -20 |
| Tax | -0 | -0 | -0 | -79 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -6 | 0 | -123 | -224 | -26 | -19 | -93 | -63 | -47 | -20 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 30 | 75 | 80 | 80 | 3.987 | 4.953 | 8.896 | 9.326 |
| Equity | -3 | -3 | -126 | -350 | -376 | -395 | 3.512 | 3.449 | 7.402 | 7.381 |
| Long-term debt | 0 | 0 | 0 | 384 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3 | 3 | 156 | 41 | 456 | 475 | 475 | 1.505 | 1.495 | 1.945 |
| Total debt | 3 | 3 | 156 | 425 | 456 | 475 | 475 | 1.505 | 1.495 | 1.945 |
EBITDA margin
-2049900.0%
This company
15.8%
Market median
-12974151% vs market
20152024
Equity ratio
79.1%
This company
38.2%
Market median
+107% vs market
20152024
Return on equity
-0.3%
This company
18.4%
Market median
-102% vs market
20152024
Net profit margin
-2049900.0%
This company
8.1%
Market median
-25307507% vs market
20152024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-11-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DM Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PETER BANG HOLDING ApS | Company | 25.0% | 25.0% | 2023 |
LARS NYENSTAD ApS | Company | 20.0% | 20.0% | 2025 |
LouMar ApS | Company | 20.0% | 20.0% | 2025 |
BENDIX-HOLDING ApS | Company | 20.0% | 20.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PETER BANG HOLDING ApS
PULMOPHARMA ApS Board members of PULMOPHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dan Mønster Nielsen | Management | 0 companies |
| Torben Ballegaard Sørensen | Chairman | 0 companies |
| Peter Frithjof Bang | Board of Directors | 0 companies |
| Per Bendix Jeppesen | Board of Directors | 0 companies |